Gujiansan Ameliorates Avascular Necrosis of the Femoral Head by Regulating Autophagy via the HIF-1α/BNIP3 Pathway
Table 2
Concentrations of OC, BAP, TRACP-5b, NTX-1, and CTX-1 in each group on the 2nd, 4th, and 8th weeks (n = 6).
Groups
Week
OC (pg/ml)
BAP (ng/ml)
TRACP-5b (ng/ml)
NTX-1 (ng/ml)
CTX-1 (pg/ml)
Normal
2
136.05 ± 3.81
12.50 ± 0.40
4.58 ± 0.21
6.64 ± 1.20
415.40 ± 24.42
4
133.59 ± 5.67
11.64 ± 0.66
4.90 ± 0.36
7.60 ± 1.22
404.77 ± 25.58
8
131.55 ± 4.77
12.66 ± 0.83
4.99 ± 0.46
7.80 ± 1.15
428.93 ± 23.21
Model
2
8.78 ± 2.13
0.70 ± 0.41
0.22 ± 0.065
2.98 ± 0.17
152.78 ± 7.81
4
7.31 ± 2.48
0.76 ± 0.28
0.18 ± 0.041
2.81 ± 0.14
157.25 ± 11.04
8
10.35 ± 3.31
0.86 ± 0.51
0.20 ± 0.066
2.95 ± 0.19
154.90 ± 10.63
L-Gujiansan
2
22.35 ± 5.46#
1.63 ± 0.15#
0.42 ± 0.10#
3.30 ± 0.073#
171.32 ± 4.31#
4
23.50 ± 3.46#
2.19 ± 0.59#▼
0.72 ± 0.11#▼
3.46 ± 0.072#
182.30 ± 13.60#
8
26.90 ± 6.84#▼
2.35 ± 0.31#▼
0.84 ± 0.13#▼
3.51 ± 0.15#▼
192.53 ± 4.28#▼
M-Gujiansan
2
40.58 ± 3.97#&
3.03 ± 0.30#
0.83 ± 0.12#&
3.50 ± 0.11#&
201.53 ± 12.10#&
4
40.77 ± 7.07#&
3.58 ± 0.57#&
1.06 ± 0.26#&▼
3.83 ± 0.33#&
220.85 ± 11.78#&▼
8
48.06 ± 2.36#&▼
3.71 ± 0.27#&▼
1.10 ± 0.19#&▼
3.83 ± 0.12#&▼
225.88 ± 12.96#&▼
H-Gujiansan
2
54.33 ± 4.99#&
4.16 ± 0.26#&
1.51 ± 0.23#&
4.24 ± 0.24#&
230.83 ± 8.37#&
4
54.22 ± 3.47#&
5.07 ± 0.27#&▼
1.59 ± 0.18#&
4.36 ± 0.47#&
241.90 ± 7.60#&▼
8
58.55 ± 4.96#&▼
5.11 ± 0.34#&▼
1.71 ± 0.24#&▼
4.40 ± 0.25#&
247.99 ± 11.14#&▼
Pravastatin
2
64.76 ± 9.53#
6.15 ± 0.69#
2.18 ± 0.35#
4.68 ± 0.063#
261.37 ± 7.17#
4
70.42 ± 10.58#
6.17 ± 0.81#
2.21 ± 0.19#
4.80 ± 0.19#
267.53 ± 13.37#
8
72.72 ± 4.22#▼
7.09 ± 0.49#▼
2.70 ± 0.14#▼
5.09 ± 0.13#▼
282.93 ± 18.49#▼
Data are represented as the means ± SD (n = 6). vs. the normal group. # vs. the model group. & vs. L-Gujiansan corresponding weeks’ group. ▼ vs. corresponding 2 weeks’ group.